Patents by Inventor Tomohiro Danjo

Tomohiro Danjo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11447471
    Abstract: An object of the present invention is to provide an ?,?-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like. The ?,?-unsaturated amide compound represented by the following formula (I) or a pharmaceutically acceptable salt or the like thereof has anticancer activity and the like: [wherein, “A” represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents —O—, —S—, —SO2—, —NRX1— (wherein, RX1 represents hydrogen atom or lower alkyl), —CHRX2— (wherein, RX2 represents hydrogen atom or hydroxy), —CH?CH—, ?CO— or —NH—CO—, and n1 and n2 are the same or different, and each represents 0 or 1].
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: September 20, 2022
    Assignee: KYOWA KIRIN CO., LTD.
    Inventors: Tomohiro Danjo, Hiroki Yamada, Takahiro Nakajima
  • Patent number: 11332455
    Abstract: The present invention provides an ?,?-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like represented by the following formula (I): [wherein, “A” represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents —O—, —S—, —SO2—, —NRX1— (wherein, RX1 represents hydrogen atom or lower alkyl), —CHRX2— (wherein, RX2 represents hydrogen atom or hydroxy), —CH?CH—, —CO— or —NH—CO—, and n1 and n2 are the same or different, and each represents 0 or 1].
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: May 17, 2022
    Assignee: KYOWA KIRIN CO., LTD.
    Inventors: Tomohiro Danjo, Katsuaki Fujiwara, Tomoyuki Nishikawa, Takahiro Nakajima, Nobumasa Otsubo, Toshihiro Seike
  • Publication number: 20210380551
    Abstract: The present invention provides an ?,?-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like represented by the following formula (I): [wherein, “A” represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents —O—, —S—, —SO2—, —NRX1— (wherein, RX1 represents hydrogen atom or lower alkyl), —CHRX2— (wherein, RX2 represents hydrogen atom or hydroxy), —CH?CH—, —CO— or —NH—CO—, and n1 and n2 are the same or different, and each represents 0 or 1].
    Type: Application
    Filed: September 28, 2020
    Publication date: December 9, 2021
    Applicant: KYOWA KIRIN CO., LTD.
    Inventors: Tomohiro DANJO, Katsuaki FUJIWARA, Tomoyuki NISHIKAWA, Takahiro NAKAJIMA, Nobumasa OTSUBO, Toshihiro SEIKE
  • Publication number: 20210155612
    Abstract: An object of the present invention is to provide an ?,?-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like. The ?,?-unsaturated amide compound represented by the following formula (I) or a pharmaceutically acceptable salt or the like thereof has anticancer activity and the like: [wherein, “A” represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents —O—, —S—, —SO2—, —NRX1— (wherein, RX1 represents hydrogen atom or lower alkyl), —CHRX2— (wherein, RX2 represents hydrogen atom or hydroxy), —CH?CH—, ?CO— or —NH—CO—, and n1 and n2 are the same or different, and each represents 0 or 1].
    Type: Application
    Filed: June 22, 2018
    Publication date: May 27, 2021
    Applicant: KYOWA KIRIN CO., LTD.
    Inventors: Tomohiro DANJO, Hiroki YAMADA, Takahiro NAKAJIMA
  • Patent number: 10787428
    Abstract: The present invention provides an ?,?-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like represented by the following formula (I): [wherein, “A” represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents —O—, —S—, —SO2—, —NRX1— (wherein, RX1 represents hydrogen atom or lower alkyl), —CHRX2— (wherein, RX2 represents hydrogen atom or hydroxy), —CH?CH—, —CO— or —NH—CO—, and n1 and n2 are the same or different, and each represents 0 or 1].
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: September 29, 2020
    Assignee: KYOWA KIRIN CO., LTD.
    Inventors: Tomohiro Danjo, Katsuaki Fujiwara, Tomoyuki Nishikawa, Takahiro Nakajima, Nobumasa Otsubo, Toshihiro Seike
  • Publication number: 20190010136
    Abstract: The present invention provides an ?,?-unsaturated amide compound or a pharmaceutically acceptable salt or the like thereof having anticancer activity and the like represented by the following formula (I): [wherein, “A” represents optionally substituted heterocyclic diyl, R1 represents hydrogen atom or optionally substituted lower alkyl, R2 represents optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted aliphatic heterocyclic group or optionally substituted aromatic heterocyclic group, X represents —O—, —S—, —SO2—, —NRX1— (wherein, RX1 represents hydrogen atom or lower alkyl), —CHRX2— (wherein, RX2 represents hydrogen atom or hydroxy), —CH?CH—, —CO— or —NH—CO—, and n1 and n2 are the same or different, and each represents 0 or 1].
    Type: Application
    Filed: December 22, 2016
    Publication date: January 10, 2019
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Tomohiro DANJO, Katsuaki FUJIWARA, Tomoyuki NISHIKAWA, Takahiro NAKAJIMA, Nobumasa OTSUBO, Toshihiro SEIKE
  • Patent number: 9540366
    Abstract: The ring-fused heterocyclic compound or a pharmaceutically acceptable salt thereof according to the present invention has a T-type calcium channel regulatory effect, and is useful, for example, as a medicament for treating and/or preventing pruritus. The present invention provides a ring-fused heterocyclic compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof and the like which has a T-type calcium channel regulatory effect and is useful as a therapeutic and/or preventive agent for pruritus, and the like.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: January 10, 2017
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Takayuki Furuta, Takashi Sawada, Tomohiro Danjo, Takahiro Nakajima, Noriaki Uesaka
  • Publication number: 20150284384
    Abstract: The ring-fused heterocyclic compound or a pharmaceutically acceptable salt thereof according to the present invention has a T-type calcium channel regulatory effect, and is useful, for example, as a medicament for treating and/or preventing pruritus. The present invention provides a ring-fused heterocyclic compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof and the like which has a T-type calcium channel regulatory effect and is useful as a therapeutic and/or preventive agent for pruritus, and the like.
    Type: Application
    Filed: July 31, 2013
    Publication date: October 8, 2015
    Inventors: Takayuki Furuta, Takashi Sawada, Tomohiro Danjo, Takahiro Nakajima, Noriaki Uesaka
  • Patent number: 9000186
    Abstract: A ring-fused heterocyclic derivative represented by the following general formula (I) or a pharmaceutically acceptable salt thereof having a T-type calcium channel regulatory effect and useful as a pruritus therapeutic and/or preventive agent, and the like are provided. In the general formula (I), R1 represents optionally substituted lower alkyl, and the like; R2 represents an optionally substituted cycloalkyl, and the like; Q represents a hydrogen atom, and the like; R3 represents —C(?O)NR8R9 (wherein R8 and R9 may be the same or different, and each represents a hydrogen atom, and the like), and the like; L1 represents —CR11AR11B— (wherein R11A and R11B may be the same or different, and each represents a hydrogen atom, and the like), and the like; and W1 and W2 may be the same or different, and each represents C—R12 (wherein R12 represents a hydrogen atom, and the like), and the like.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: April 7, 2015
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Takashi Sawada, Tomohiro Danjo, Keiichi Motosawa, Takayuki Furuta, Maki Ichioka, Masamori Sugawara, Noriaki Uesaka
  • Publication number: 20140038941
    Abstract: A ring-fused heterocyclic derivative represented by the following general formula (I) or a pharmaceutically acceptable salt thereof having a T-type calcium channel regulatory effect and useful as a pruritus therapeutic and/or preventive agent, and the like are provided. In the general formula (I), R1 represents optionally substituted lower alkyl, and the like; R2 represents an optionally substituted cycloalkyl, and the like; Q represents a hydrogen atom, and the like; R3 represents —C(?O)NR8R9 (wherein R8 and R9 may be the same or different, and each represents a hydrogen atom, and the like), and the like; L1 represents —CR11AR11B— (wherein R11A and R11B may be the same or different, and each represents a hydrogen atom, and the like), and the like; and W1 and W2 may be the same or different, and each represents C—R12 (wherein R12 represents a hydrogen atom, and the like), and the like.
    Type: Application
    Filed: February 1, 2012
    Publication date: February 6, 2014
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Takashi Sawada, Tomohiro Danjo, Keiichi Motosawa, Takayuki Furuta, Maki Ichioka, Masamori Sugawara, Noriaki Uesaka